Stability Testing for FDA Approved KSHNO14 (Pyridostigmine Bromide Extend – Release Tablets)

The government is conducting market research to identify potential sources capable of supporting FDA compliant stability testing for FDA approved KSHN014 (Pyridostigmine Bromide Extend – Release Tablets) 105 mg tablets. The testing includes continued continuity requirements associated with an existing ongoing stability study, with multiyear stability testing including long term and refrigerated storage conditions with stability data. The key aspects of this opportunity include: • Stability testing for FDA approved KSHN014 (Pyridostigmine Bromide Extend – Release Tablets) 105 mg tablets • Continued continuity requirements associated with an existing ongoing stability study • Multiyear stability testing including long term and refrigerated storage conditions with stability data • The study includes testing for five (5) years at CRT and ten (10) years refrigerated